Literature DB >> 10461012

Elevated thrombotic activity after myocardial infarction: A 2-year follow-up study.

V Martínez-Sales1, V Vila, E Réganon, M A Goberna, F Ferrando, M A Palencia, J Aznar.   

Abstract

This study examines the evolution of the thrombotic activity in patients with myocardial infarction (MI) treated with aspirin (200 mg/day) for 2 years after MI. Plasma samples of 10 patients were collected at 7, 30, 60, 90, 120, 150, 180, 360 and 720 days. In all the samples we measured fibrinogen (Fg), high molecular weight Fg (HMW-Fg), fibrinopeptide A (FPA), prothrombin fragment 1+2 (F1+2), beta-thromboglobulin (beta-TG), von Willebrand factor (vWF), tissue factor (TF) and TF pathway inhibitor (TFPI). The plasma Fg, HMW-Fg, FPA, F1+2, beta-TG and vWF levels were significantly elevated in the patients at the beginning of the study as compared to the normal group. The 95% confidence intervals were Fg 277-333 mg/dl, HMW-Fg 200-244 mg/dl, FPA 5.3-16.5 ng/ml, F1+2 1.4-1.8 nmol/l, beta-TG 110-118 IU/ml and vWF 139-195%. At thirty days Fg and HMW-Fg returned to normal levels, whereas the increase in FPA and F1+2 levels persisted throughout the study. At 120 and 150 days, respectively, beta-TG and vWF returned to normal levels. The increase in thrombin generation and activity pointed to a persistent hypercoagulable state 2 years after MI. Plasma levels of TF and TFPI showed no statistically significant variations with respect to the normal values over the 2-year period studied. In conclusion, these results suggest a persistent generation and activity of thrombin and cellular activation in these patients after MI.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 10461012     DOI: 10.1159/000022446

Source DB:  PubMed          Journal:  Haemostasis        ISSN: 0301-0147


  5 in total

1.  ImpaCt of aspirin regimen on THrombin generation in diabEtic patients with acute coronary syndrome: CARTHaGE-ACS trial.

Authors:  Amine Boussofara; Lobna Laroussi; Hela Baccouche; Emna Bennour; Sami Kasbaoui; Hbib Triki; Ibn El Haj Zied; Ikram Kammoun; Afef Ben Halima; Faouzi Addad; Sonia Marrakchi; Neila Ben Romdhane; Salem Kachboura
Journal:  Eur J Clin Pharmacol       Date:  2020-08-06       Impact factor: 2.953

2.  Understanding prognostic benefits of exercise and antidepressant therapy for persons with depression and heart disease: the UPBEAT study--rationale, design, and methodological issues.

Authors:  James A Blumenthal; Andrew Sherwood; Sharon D Rogers; Michael A Babyak; P Murali Doraiswamy; Lana Watkins; Benson M Hoffman; Cara O'Connell; Julie J Johnson; Seema M Patidar; Robert Waugh; Alan Hinderliter
Journal:  Clin Trials       Date:  2007       Impact factor: 2.486

3.  Platelet and endothelial activity in comorbid major depression and coronary artery disease patients treated with citalopram: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Efficacy Trial (CREATE) biomarker sub-study.

Authors:  Louis T van Zyl; Francois Lespérance; Nancy Frasure-Smith; Alex I Malinin; Dan Atar; Marc-André Laliberté; Victor L Serebruany
Journal:  J Thromb Thrombolysis       Date:  2008-01-11       Impact factor: 2.300

Review 4.  Duration of dual antiplatelet therapy in acute coronary syndrome.

Authors:  Simon John Wilson; David E Newby; Dana Dawson; John Irving; Colin Berry
Journal:  Heart       Date:  2017-03-01       Impact factor: 5.994

5.  Thrombin Generation and Atherothrombosis: What Does the Evidence Indicate?

Authors:  Hugo Ten Cate; H Coenraad Hemker
Journal:  J Am Heart Assoc       Date:  2016-08-08       Impact factor: 5.501

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.